doxazosin
Selected indexed studies
- Doxazosin Attenuates Liver Fibrosis by Inhibiting Autophagy in Hepatic Stellate Cells via Activation of the PI3K/Akt/mTOR Signaling Pathway. (Drug Des Devel Ther, 2021) [PMID:34456560]
- Doxazosin and congestive heart failure. (Congest Heart Fail, 2002) [PMID:12045387]
- Doxazosin in the current treatment of hypertension. (Expert Opin Pharmacother, 2008) [PMID:18312163]
_Worker-drafted node — pending editorial review._
Connections
doxazosin is a side effect of
Sources
- Doxazosin Attenuates Liver Fibrosis by Inhibiting Autophagy in Hepatic Stellate Cells via Activation of the PI3K/Akt/mTOR Signaling Pathway. (2021) pubmed
- Doxazosin and congestive heart failure. (2002) pubmed
- Doxazosin in the current treatment of hypertension. (2008) pubmed
- Doxazosin gastrointestinal therapeutic system: a review of its use in benign prostatic hyperplasia. (2005) pubmed
- Doxazosin in the treatment of benign prostatic hypertrophy: an update. (2006) pubmed
- Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. (1995) pubmed
- Doxazosin: a new approach to hypertension and benign prostatic hyperplasia. (1996) pubmed
- Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension. (1988) pubmed
- Doxazosin and congestive heart failure. (2001) pubmed
- Doxazosin as combination therapy for patients with stage 1 and stage 2 hypertension. (2003) pubmed